An interventional study of Transcranial Direct Current Therapy (tDCS) and Sham (No Treatment) in COVID-19, Long COVID and Long Covid19, sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir. Recruiting at 2 sites in Spain. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Fundación Universidad Católica de Valencia San Vicente Mártir · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 14th largest by planned enrollment of the 39 interventional ones that give a count, is one of 12 that started in 2023, is one of 31 with no phase, reaches primary completion later than 10 of the 15 other live ones, and was the 21st registered.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18–65
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
Instituto de Investigación Sanitaria Aragón · Sites in Spain
Ages 18+
Universidad Rey Juan Carlos · Sites in Spain
Ages 18+
Hellenic Institute for the Study of Sepsis · Sites in Spain, Germany, Greece and 1 more country
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 1
First in 2021; this study’s year is marked. 12 started in 2023.
This study's planned enrollment of 87 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 60 across the 39 interventional studies, 184 across the 13 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 52 have an industry lead sponsor. The 10 most frequent:
Fundación Universidad Católica de Valencia San Vicente Mártir is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
Fundación Universidad Católica de Valencia San Vicente Mártir has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Post-Acute COVID-19 Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07530757Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition | 2026-11 |
| NCT06928480Instituto de Investigación Sanitaria AragónEffectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19. | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and myalgia, as well as sleep problems. Transcranial direct current stimulation is used in the field of Physiotherapy and Rehabilitation, with results that have proven to be effective for treating patients suffering from symptoms like migraines, headaches, chronic pain, fibromyalgia, or chronic neuropathic pain and insomnia. As you can see, in the case of patients with Long Covid, we find several of these symptoms, so it is suggested that if transcranial direct current therapy (TDCS) gives such good results in relieving these symptoms, why couldn't it give such good results and help just as much in patients with Long Covid, since many of the symptoms are the same, even if the origin or cause is different.
Study extension (amendment to protocol UCV/2021-2022/140, approved by the Research Ethics Committee of the Catholic University of Valencia, ref. UCV/2022-2023/072, on October 28, 2024). After the initial phase, in which participants with Long COVID received anodal tDCS, the study was extended to a randomized, sham-controlled, double-blind phase. Participants are randomized 1:1:1:1 to anodal (original arm, recruitment continued), bifrontal, cathodal or sham tDCS. Objectives, eligibility criteria and primary outcome are unchanged. Planned enrollment: initial phase, 27 participants; randomized extension phase, 60 participants (15 per arm). Between-group comparisons will include only participants randomized in the extension phase; initial-phase data will be reported separately and used only in supplementary analyses within the anodal tDCS arm. Sleep outcomes (PSQI, ISI, ESS) were added as secondary outcomes in the extension phase only.
The initial phase was approved by the Research Ethics Committee of the Catholic University of Valencia (ref. UCV/2021/2022/140); the extension was approved by the Research Ethics Committee of the Catholic University of Valencia (ref. UCV/2022-2023/072) on October 28, 2024.
606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
This study's planned enrollment of 87 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Browse Post-Acute COVID-19 Syndrome studies →Fundación Universidad Católica de Valencia San Vicente Mártir is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
Compared within Post-Acute COVID-19 Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is COVID-19. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Same electrode montage as another arm; current ramped up and down, then switched off, to mimic the sensations of active stimulation.
Device: Sham (No Treatment)
Original arm. Anode over M1/C3, cathode over Fp2
Device: Transcranial Direct Current Therapy (tDCS)
Cathode over M1/C3, anode over Fp2; same intensity, duration and number of sessions.
Device: Transcranial Direct Current Therapy (tDCS)
Anode over F3, cathode over F4; same intensity, duration and number of sessions.
Device: Transcranial Direct Current Therapy (tDCS)
Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential. Each session lasts between 20 and 30 minutes, and approximately 20 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA. The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment.
Same electrode montage as other arm; current ramped up and then down, then switched off, to mimic the sensations of active stimulation. Same session schedule as active arms.
CHANGE FROM PRE-TREATMENT DEGREE CHRONIC BODY PAIN AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS
MEASURED WITH 2 SPECIFIC PAIN SCALES (EVA-Visual Analog SCALE AND MCGILL PAIN QUESTIONNAIRE). EVA SCALE (0 no pain-10 maximun pain). MCGILL QUESTIONNAIRE (0 no pain-66 maximun pain)
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
CHANGE FROM PRE-TREATMENT INTENSE MIGRAINES OR HEADACHES AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS
MEASURED WITH 2 SPECIFIC SCALES (MIDAS-Migraine dissability Assessment SCALE AND HIT-6 QUESTIONNAIRE-headache impact test). MIDAS SCALE (0 nil disability - \>21 severe disability). HIT-6 QUESTIONNAIRE (0 no impact - \>60 very severe impact).
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
CHANGE FROM PRE-TREATMENT QUALITY OF LIFE (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS
MEASURED WITH 1 SPECIFIC SCALE (SF-12 QUESTIONNAIRE). (0 worst quality of life - 100 best quality of life)
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
CHANGE FROM PRE-TREATMENT MOOD AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS
MEASURED WITH 1 SPECIFIC SCALE (EVEA-mood rating SCALE). (0 nothing - 10 a lot)
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
CHANGE FROM PRE-TREATMENT SLEEP QUALITY (SF-12 QUESTIONNAIRE) AT INMEDIATE POST-TREATMENT, 1 MONTH, 3 MONTHS AND 6 MONTHS
MEASURED WITH 3 SPECIFIC SCALES (ISI-Insomnia Severity Index, Pittsburg Sleep Quality Index AND Epworth Sleepiness Scale). ISI (0-7 no insomnia, 8-14 subclinical insomnia, 15-21 moderated insomnia, 22-28 severe insomnia). PITTSBURG (0-4 good sleep quality, \> 5 sleep problems). EPWORTH (0-10 normal sleepiness, 11-14 mild daytime sleepiness, 15-18 moderate daytime sleepiness, 19-24 severe daytime sleepiness).
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT / POST-TREATMENT 1 MONTH / 3 MONTHS / 6 MONTHS
BRAIN RESILIENCE (EEG-TMS) AT PRE-TREATMENT AND INMEDIATE POST-TREATMENT
EEG-TMS AND PPTMS PRE-TREATMENT AND INMEDIATE POST-TREATMENT
Time frame: PRE-TREATMENT / IMMEDIATE POST-TREATMENT
Plan to share: No
Started Apr 2023 (actual). Primary completion is estimated for Nov 2026, 43 months after the start.
Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 43 months is above that.
Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Jul 2023 → Nov 2026 and completion Jul 2023 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Fundación Universidad Católica de Valencia San Vicente Mártir